Investor’s Delight: Celldex Therapeutics Inc. (CLDX) Closes Weak at 30.28, Down -3.32

Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The closing price of Celldex Therapeutics Inc. (NASDAQ: CLDX) was $30.28 for the day, down -3.32% from the previous closing price of $31.32. In other words, the price has decreased by -$3.32 from its previous closing price. On the day, 1.07 million shares were traded. CLDX stock price reached its highest trading level at $31.6599 during the session, while it also had its lowest trading level at $30.15.

Ratios:

Our analysis of CLDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 29.36 and its Current Ratio is at 29.36. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on October 07, 2024, initiated with a Buy rating and assigned the stock a target price of $70.

On September 30, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $45.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 14 ’24 when Martin Samuel Bates sold 17,172 shares for $35.42 per share. The transaction valued at 608,315 led to the insider holds 28,125 shares of the business.

Crowley Elizabeth sold 30,000 shares of CLDX for $1,045,962 on Jun 14 ’24. The SR. VP & CPDO now owns 9,074 shares after completing the transaction at $34.87 per share. On Jun 07 ’24, another insider, Crowley Elizabeth, who serves as the SR. VP & CPDO of the company, sold 15,000 shares for $35.06 each. As a result, the insider received 525,873 and left with 9,074 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 2076127232 and an Enterprise Value of 1207256448. For the stock, the TTM Price-to-Sale (P/S) ratio is 241.84 while its Price-to-Book (P/B) ratio in mrq is 2.47. Its current Enterprise Value per Revenue stands at 145.4 whereas that against EBITDA is -7.536.

Stock Price History:

Over the past 52 weeks, CLDX has reached a high of $53.18, while it has fallen to a 52-week low of $22.11. The 50-Day Moving Average of the stock is -16.94%, while the 200-Day Moving Average is calculated to be -21.42%.

Shares Statistics:

CLDX traded an average of 983.14K shares per day over the past three months and 844850 shares per day over the past ten days. A total of 66.29M shares are outstanding, with a floating share count of 64.21M. Insiders hold about 3.14% of the company’s shares, while institutions hold 103.47% stake in the company. Shares short for CLDX as of 1727654400 were 8306171 with a Short Ratio of 8.45, compared to 1724976000 on 8571341. Therefore, it implies a Short% of Shares Outstanding of 8306171 and a Short% of Float of 14.499999999999998.

Most Popular